NextCure Inc（NXTC）の株式分析NXTCNextCure Inc

NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NextCure Inc is not a good buy right now due to its current price of $5.30, which is significantly below its 52-week high of $15.74, indicating a potential for recovery but also substantial risk. The RSI is at 39.99, suggesting the stock is nearing oversold conditions, but the recent performance shows a 60.09% year-to-date decline, indicating ongoing weakness. The main risk is the substantial net losses reported, with a net income of -11603000 in Q4 2024 and -26808000 in Q2 2025, which raises concerns about the company's financial health and sustainability.